Oncology
Refine Search
Biotechnology
China’s Innovent Biologics recently presented Phase I study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer. 14 June 2024
Pharmaceutical
Bladder cancer specialist UroGen Pharma saw its shares close up nearly 38% at $17.50 yesterday, after it shared positive trial results on its lead pipeline candidate UGN-102, an innovative formulation of mitomycin. 14 June 2024
Biotechnology
Xencor has announced it will regain exclusive worldwide rights to plamotamab, a CD20 x CD3 bispecific T-cell engager. 14 June 2024
Biotechnology
The US Food and Drug Administration (FDA) yesterday granted traditional approval for US pharma major Eli Lilly’s Retevmo (selpercatinib). 13 June 2024
Biosimilars
Icelandic company Alvotech and Germany’s STADA Arzneimittel are strengthening their existing strategic alliance for biosimilars by extending their partnership to cover AVT03. 13 June 2024
Biotechnology
Italy’s Sibylla Biotech and The University of Texas MD Anderson Cancer Center have announced a strategic collaboration. 12 June 2024
Pharmaceutical
Helsinn Group and Chugai Pharma Europe have announced the renewal of their distribution and license agreement for Akynzeo (netupitant-palonosetron) in the UK and Ireland. 12 June 2024
Biotechnology
The Center for Drug Evaluations of the National Medical Products Administration (NMPA) in China has accepted the biologics license application (BLA) for zanidatamab for second-line treatment of HER2-positive biliary tract cancer (BTC). 11 June 2024
Biotechnology
UK pharma major GSK and US biotech SpringWorks Therapeutics are to end their collaboration combining Blenrep (belantamab mafodotin) and Ogsiveo (nirogacestat). 11 June 2024
Biotechnology
German clinical-stage cancer drug developer Thermosome has appointed Dr Sabine Hauck as chief technology officer (CTO). 11 June 2024
Pharmaceutical
British pharma major AstraZeneca's bid to broaden the label for Tagrisso (osimertinib) will be considered under the Priority Review scheme. 10 June 2024
Biotechnology
Swiss pharma giant Roche (ROG: SIX) has announced that the European Commission (EC) has approved Alecensa (alectinib) monotherapy, as adjuvant treatment following tumor resection for adults with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) at high risk of recurrence. 10 June 2024
Biotechnology
Shares of Replimune closed up nearly 28% at $7.11 on Thursday after the company shared data on its oncolytic virus RP1 (vusolimogene oderparepvec), in combination with Bristol Myers Squibb’s Opdivo (nivolumab), 7 June 2024
Biotechnology
Chicago, USA-based biopharma giant AbbVie has announced encouraging top-line results from its Phase II PICCOLO trial of Elahere (mirvetuximab soravtansine). 7 June 2024
Pharmaceutical
The US Food and Drug Administration (FDA) late Thursday announced the approved of Geron Corporation’s Rytelo (imetelstat), an oligonucleotide telomerase inhibitor. 7 June 2024
Biotechnology
UK-based AI-driven precision medicines company Exscientia today announced the appointment of two technology and clinical development leaders to senior roles. 6 June 2024
Pharmaceutical
Australian radiopharma developer Telix Pharmaceuticals has announced the launch of its initial public offering in the USA of 17,000,000 American Depositary Shares (ADSs), each representing one ordinary share in Telix. 6 June 2024
Biotechnology
Isotope Technologies Munich (ITM) has announced an equity investment of 188 million euros ($204 million) led by Temasek with participation from funds managed by BlackRock, Qatar Investment Authority, ATHOS and Carbyne. 6 June 2024
Biotechnology
USA-based ArriVent BioPharma has entered into a collaboration agreement with a unit of Chinese biotech Alphamab Oncology, to discover, develop and commercialize novel antibody-drug conjugates (ADCs) for the treatment of cancers. 6 June 2024
Pharmaceutical
Italy’s Philogen and Indian drugmaker Sun Pharmaceutical Industries have submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the approval of Nidlegy (daromun). 5 June 2024
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze